China growth and global non-US Internet equities

Blue Lotus Research Institute

Blue Lotus Research is a Hong Kong Type 4 Licensed investment advisory firm focusing on Chinese growth equities and global non-US Internet equities

[Akeso Inc. (9926 HK, BUY, TP HK$63) TP Change]: Too Many Positives to Count…Reiterate TOP BUY

Akeso Placement - Opportunistic Raise, past Deal Record Has Been Mixed but Relative Size Is Small

[Blue Lotus Healthcare Sector Update]: Bottom-Fishing at the Bottom of the Business Cycle

Is Akeso's Sell-Off a Long Waited Opportunity or a Long Overdue Correction?

[Akeso (9926 HK, BUY, TP HK$58) Company Update]: AK112’s Win Unleashes Change in PD-1/L1 Landscape

Blue Lotus China New Economy Research, Blue Lotus Research Institute

Eric Wen

Blue Lotus China New Economy Research

Equity Bottom-Up

<ul>
<li>Cadonilimab (AK104)(PD-1/CTLA-4) achieved 7.1% market share in China's PD-1(L1) market in 2023, up from 3.4% in 2022, ranking it No.4 in revenue market share after Tislelezumab, Keytruda and Sintilimab;</li>
<li>With six days to go, the chance to receives NMPA approval for Gastric Cancer is slim, which means the June 18 price cut is for the existing Cervical Cancer indication;</li>
<li>The big question is the price elasticity <em>following</em> Cadonilimab's inclusion to NDRL. With ~110K new patients each year and only ~2,100 receiving Cadonilimab, we expect a moderate price cut.</li>
</ul>


Cadonilimab (AK104)(PD-1/CTLA-4) achieved 7.1% market share in China's PD-1(L1) market in 2023, up from 3.4% in 2022, ranking it No.4 in revenue market share after Tislelezumab, Keytruda and Sintilimab;
With six days to go, the chance to receives NMPA approval for Gastric Cancer is slim, which means the June 18 price cut is for the existing Cervical Cancer indication;
The big question is the price elasticity following Cadonilimab's inclusion to NDRL. With ~110K new patients each year and only ~2,100 receiving Cadonilimab, we expect a moderate price cut.


Harbin Gloria Pharmaceuticals Co, Ltd. (002437 CH)

What's Behind Akeso's Cadonilimab Price Cut and What's Next?

Akeso Biopharma Inc

What's Behind Akeso's Cadonilimab Price Cut and What's Next?